Clinical Trials - September 17, 2025
AnaCardio completes target enrollment in Phase 2a study
AnaCardio has announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025.
Clinical Trials - September 15, 2025
Cinclus Pharma screens first patient in Phase III trial
The first patient has been screened in the company's HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease (GERD).
Clinical Trials - September 8, 2025
Orexo announces positive in vivo data
The company has announced pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology.
Clinical Trials - September 1, 2025
SweTrial is a reality
The government decided in the end of July 2025 to establish the SweTrial partnership, an initiative aimed to strengthen Sweden's role as a life science nation and make it easier to conduct clinical trials in the country.
Clinical Trials - August 27, 2025
Active lymphoma eliminated in 4 out of 6 patients in Elicera’s CARMA study
Elicera Therapeutics has announced preliminary data from the first two cohorts of the ongoing Phase I/IIa CARMA study with ELC-301.
Clinical Trials - August 4, 2025
Hansa Biopharma announces new supportive trial data
The company has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta’s ELEVIDYS in the SRP-9001-104 trial.
